10th new indication for Humira approved by FDA

US pharma major AbbVie (NYSE: ABBV) says that the US Food and Drug Administration has approved Humira (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis.

Humira, the world’s biggest-selling drug with 2015 revenues of $14 billion, is now the first and only FDA-approved non-corticosteroid therapy available for adults with non‑infectious intermediate, posterior and panuveitis. This approval marks the 10th approved indication for Humira in the USA for immune-mediated diseases.

This month, the European Commission also approved Humira in the European Union for the treatment of non‑infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.